DYSLIPIDEMIA

Manganese
Cofactor to an antioxidant (superoxide dismutase) that repairs damage to blood vessels caused by oxidized LDL (low density lipoprotein). [1,2]

Magnesium
Deficiency causes pro-atherogenic (heart-disease causing) changes in lipoprotein metabolism; Protects LDL (low density lipoprotein) from being oxidized. [3,4]

Vitamin C
Protects LDL from oxidation, thus making it less "sticky" and prone to atherosclerosis (clogging of arteries); Prevents white blood cells (monocytes) and oxidized LDL from sticking to blood vessel wall; Lowers Lp(a) in some people. [5,6,7]

Vitamin D
Suppresses foam cell formation thus reducing risk of lipid-related arterial blockages; Deficiency linked to dyslipidemia. [8,9]

Zinc
Suboptimal zinc raises dangerous lipoproteins that promote vascular inflammation and arterial plaque formation; Cellular zinc controls the gene that makes heart-protective HDL (high density lipoprotein). [34,35,36]

Vitamin B3
Niacin (B3) effectively lowers the highly atherogenic Lp(a) by decreasing its rate of synthesis in the liver. [10,11]

Selenium
Prevents post-prandial (after a meal) changes in lipoproteins that make them susceptible to oxidation and thus harmful. [32,33]

Vitamin B5
Favorably alters low density lipoprotein metabolism and reduces triglycerides; Full benefit of lipid lowering effects may not be seen for up to four months. [12,13]

Copper
Several copper-dependent enzymes affect lipoprotein metabolism; Deficiency contributes to fatty buildup in arteries caused by dyslipidemia. [29,30,31]

Carnitine
In supplementation trials, carnitine lowers triglycerides, oxidized LDL and the atherogenic Lp(a); This effect is likely due to its role in transporting fatty acids into cells so they can be used as fuel. [14,15,16]

Coenzyme Q10
It is well established that statins, often prescribed for dyslipidemia, deplete CoQ10; Lowers Lp(a) and improves efficacy of some dyslipidemia meds. [27,28]

Chromium
Specifically improves the dyslipidemia that accompanies insulin resistance; May increase HDL; Synergistic effect with niacin (B3) for dyslipidemia. [24,25,26]

Choline
Regulates HDL metabolism; Part of the enzyme lecithin-cholesterol acyltransferase that has a major impact on lipoprotein metabolism. [22,23]

Inositol
Decreases small, dense LDL especially in patients with metabolic syndrome; Lowers triglycerides. [19,20,21]

Lipoic Acid
Improves lipid profile by reducing small, dense LDL (dangerous type); Protects vascular lining from oxidized cholesterol. [17,18]

Additional nutrients affect lipid metabolism. This list is non-exhaustive.

REFERENCES

[1]Takabe W, Li R, Ai L et al. Oxidized low-density lipoprotein-activated c-Jun NH2-terminal kinase regulates manganese superoxide dismutase ubiquitination: implication for mitochondrial redox status and apoptosis. Arterioscler Thromb Vasc Biol. 2010;30:436-41

[2]Perrotta I, Perrotta E, Sesti S et al. MnSOD expression in human atherosclerotic plaques: an immunohistochemical and ultrastructural study. Cardiovasc Pathol 2013;Epub ahead of print.

[3]Maier J. Low magnesium and atherosclerosis: an evidence-based link. Mol Aspects Med 2003;24:137-146.

[4]Sherer Y, Bitzur R, Cohen H et al. Mechanisms of action of the anti-atherogenic effect of magnesium: lessons from a mouse model. Magnes Res 2001;14:173-179.

[5]Woollard K, Loryman C, Meredith E et al. Effects of oral vitamin C on monocyte: endothelial cell adhesion in healthy subjects. Biochem Biophys Res Commun 2002;294:1161-1168.

[6]Shariat S, Mostafavi S, Khakpour F. Antioxidant effects of vitamins C and e on the low-density lipoprotein oxidation mediated by myeloperoxidase. Iran Biomed J 2013;17:22-28.

[7]Rath M. Lipoprotein-a reduction by ascorbate. J Orthomolec Med 1992;7:81-82.

[8]Riek A, Oh J, Bernal-Mizrachi C. Vitamin D regulates macrophage cholesterol metabolism in diabetes. J Steroid Biochem Mol Biol 2010;121:430-433.

[9]Guasch A, Bulló M, Rabassa A et al. Plasma vitamin D and parathormone are associated with obesity and atherogenic dyslipidemia: a cross-sectional study. Cardiovasc Diabeto. 2012;11:149.

[10]Seed M, O'Connor B, Perombelon N et al. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993;101:61-68.

[11]Kostner K, Gupta S. Niacin: a lipid polypill? Expert Opin Pharmacother 2008;9:2911-20.

[12]Rumberger J, Napolitano J, Azmumano I et al. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res 2011;31:608-615.

[13]McRae M. Treatment of hyperlipoprotenemia with pantethine: a review and analysis of efficacy and tolerability. Nutr Res 2005;25:319-333.

[14]Malaguarnera M, Vacante M, Avitabile T et al. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 2009;89:71-76.

[15]Sirtori C, Calabresi L, Ferrara S et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000;10:247-251.

[16]Derosa G, Cicero A, Gaddi A et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25:1429-1439.

[17]Zhang Y, Han P, Wu N et al. Amelioration of Lipid Abnormalities by α-Lipoic acid Through Antioxidative and Anti-Inflammatory Effects. Obesity 2011;19:1647-1653.

[18]Harding S, Rideout T, Jones P. Evidence for using alpha-lipoic acid in reducing lipoprotein and inflammatory related atherosclerotic risk. J Diet Suppl 2012;9:116-127.

[19]Maeba R, Hara H, Ishikawa H et al. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J Nutr Sci Vitaminol 2008;54:196-202.

[20]Jariwalla R. Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent. Anticancer Res 1999;19:3699-702.

[21]Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 2013;17:537-40.

[22]Kunnen S, Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res 2012;53:1783-99.

[23]Vance D. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis.Curr Opin Lipidol 200819:229-34.

[24]Sundaram B, Singhal K, Sandhir R. Anti-atherogenic effect of chromium picolinate in streptozotocin-induced experimental diabetes. J Diabetes 2013;5:43-50.

[25]Sealls W, Penque B, Elmendorf J. Evidence that chromium modulates cellular cholesterol homeostasis and ABCA1 functionality impaired by hyperinsulinemia--brief report. Arterioscler Thromb Vasc Biol 2011;31:1139-40.

[26]Press R, Geller J, Evans G. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med. 1990;152:41-5.

[27]Langsjoen P, Langsjoen A. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003;18:101-11.

[28]Cicero A, Derosa G, Miconi A et al. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed Pharmacother 2005 Jul;59:312-7.

[29]Hamilton I, Gilmore W, Strain J. Marginal copper deficiency and atherosclerosis. Biol Trace Elem Res 2000;78:179-89.

[30]DiSilvestro R, Joseph E, Zhang W et al. A randomized trial of copper supplementation effects on blood copper enzyme activities and parameters related to cardiovascular health. Metabolism 2012;61:1242-6.

[31]Wildman R, Mao S. Tissue-specific alterations in lipoprotein lipase activity in copper-deficient rats. Biol Trace Elem Res 2001;80:221-9.

[32]Natella F, Fidale M, Tubaro F et al. Selenium supplementation prevents the increase in atherogenic electronegative LDL (LDL minus) in the postprandial phase. Nutr Metab Cardiovasc Dis 2007;17:649-56

[33]Kaur H, Bansal M. Studies on scavenger receptors under experimental hypercholesterolemia: modulation on selenium supplementation. Biol Trace Elem Res 2011;143:310-9.

[34]Beattie J, Gordon M, Duthie S et al. Suboptimal dietary zinc intake promotes vascular inflammation and atherogenesis in a mouse model of atherosclerosis. Mol Nutr Food Res 2012;56:1097-1105.

[35]Wu J, Wu Y, Reaves S et al. Apolipoprotein A-I gene expression is regulated by cellular zinc status in hep G2 cells. Am J Physiol. 1999;277:C537-44.

[36]Shen H, MacDonald R, Bruemmer D et al. Zinc deficiency alters lipid metabolism in LDL receptor deficient mice treated with rosiglitazone. J Nutr 2007;137:2339-45.

Additional references at http://www.spectracell.com/clinicians/clinical-education-center/online-library-mnt-hypercholesterolemia-abstracts/